Brokerages Anticipate LeMaitre Vascular, Inc. (NASDAQ:LMAT) to Announce $0.28 Earnings Per Share


Share on StockTwits

Equities research analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to post earnings of $0.28 per share for the current quarter, according to Zacks. Four analysts have made estimates for LeMaitre Vascular’s earnings, with estimates ranging from $0.27 to $0.29. LeMaitre Vascular posted earnings of $0.16 per share in the same quarter last year, which would indicate a positive year over year growth rate of 75%. The business is expected to report its next earnings report on Thursday, April 29th.

According to Zacks, analysts expect that LeMaitre Vascular will report full year earnings of $1.27 per share for the current fiscal year, with EPS estimates ranging from $1.20 to $1.40. For the next year, analysts expect that the firm will report earnings of $1.44 per share, with EPS estimates ranging from $1.35 to $1.53. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, February 25th. The medical instruments supplier reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.03. LeMaitre Vascular had a net margin of 15.41% and a return on equity of 12.32%. The firm had revenue of $37.55 million for the quarter, compared to the consensus estimate of $35.87 million.

Several research firms have commented on LMAT. KeyCorp began coverage on shares of LeMaitre Vascular in a report on Friday, February 12th. They issued a “sector weight” rating on the stock. Barrington Research raised their target price on shares of LeMaitre Vascular from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, February 26th. Roth Capital reiterated a “neutral” rating on shares of LeMaitre Vascular in a research report on Tuesday, March 2nd. Finally, Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Tuesday, March 2nd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $39.29.

Shares of NASDAQ:LMAT traded up $0.91 on Friday, hitting $49.82. The company had a trading volume of 1,442 shares, compared to its average volume of 127,335. LeMaitre Vascular has a 1-year low of $23.40 and a 1-year high of $54.96. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of 52.59, a P/E/G ratio of 3.52 and a beta of 1.43. The stock has a 50 day moving average price of $48.21 and a 200 day moving average price of $40.96. The company has a current ratio of 2.30, a quick ratio of 1.27 and a debt-to-equity ratio of 0.23.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 25th. Investors of record on Tuesday, March 9th were paid a $0.11 dividend. This represents a $0.44 dividend on an annualized basis and a yield of 0.88%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.10. The ex-dividend date of this dividend was Monday, March 8th. LeMaitre Vascular’s dividend payout ratio (DPR) is 50.00%.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 2,100 shares of the business’s stock in a transaction on Wednesday, March 10th. The shares were sold at an average price of $49.76, for a total transaction of $104,496.00. Following the sale, the chief executive officer now owns 2,692,833 shares of the company’s stock, valued at $133,995,370.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 48,150 shares of the business’s stock in a transaction on Wednesday, March 3rd. The stock was sold at an average price of $51.20, for a total transaction of $2,465,280.00. Following the sale, the chief executive officer now directly owns 2,796,567 shares in the company, valued at approximately $143,184,230.40. The disclosure for this sale can be found here. Insiders sold 132,816 shares of company stock worth $6,728,329 over the last three months. 16.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of LMAT. Fieldpoint Private Securities LLC bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $36,000. Steward Partners Investment Advisory LLC grew its stake in shares of LeMaitre Vascular by 41.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,059 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 310 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $47,000. Great West Life Assurance Co. Can grew its stake in shares of LeMaitre Vascular by 288.5% during the third quarter. Great West Life Assurance Co. Can now owns 79,671 shares of the medical instruments supplier’s stock worth $159,000 after buying an additional 59,165 shares during the last quarter. Finally, Citigroup Inc. grew its stake in shares of LeMaitre Vascular by 36.8% during the fourth quarter. Citigroup Inc. now owns 4,296 shares of the medical instruments supplier’s stock worth $174,000 after buying an additional 1,155 shares during the last quarter. 84.17% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

Featured Story: Google Finance Portfolio

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.